Zhejiang Tianyu Pharmaceutical Co., Ltd.: history, ownership, mission, how it works & makes money

Founded in 1993, Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ) has grown from an API and intermediate-focused manufacturer to a GMP- and EU-GMP-certified exporter with a diversified portfolio spanning cardiovascular, anti-diabetic, anticoagulant and respiratory APIs, six wholly-owned subsidiaries and over 4,500 employees operating across more than 470,000 m2 of production space; the company, which listed on the Shenzhen Stock Exchange in 2017, has 343.93 million shares outstanding (down 0.87% year-on-year) with insiders holding about 55.40%, institutional investors 12.89%, a market capitalization of 8.84 billion CNY and an enterprise value of 10.30 billion CNY as of September 26, 2025, while posting 2.63 billion CNY in revenue for 2024 (up 4.10%) and net income of 55.94 million CNY (up 104.45%), plus EPS of 0.16 CNY, reporting 2.29 billion CNY in revenue and 220.93 million CNY in net income for the nine months ending September 30, 2025, investing over 300 million CNY in R&D in the past year, holding 12 national/international patents, supplying more than half of its products to major domestic and global pharmaceutical firms, offering CDMO and fine-chemical services, and exhibiting a low-beta (0.59) share performance with an 80.92% 52-week price gain that underscores its robust market momentum

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ): Intro

• Core product areas:
  • APIs for cardiovascular drugs (anti-hypertensive, anticoagulants)
  • APIs for metabolic disorders (hypoglycemic, hypolipidemic)
  • Respiratory system APIs (anti-asthmatic)
  • Pharmaceutical intermediates for small-molecule synthesis

• API and intermediate manufacturing - bulk sales to generic drug manufacturers and contract customers.
• Contract development and manufacturing (CDMO/CRO-style services) - fee-for-service R&D and custom synthesis.
• Export sales - enabled by EU GMP and other certifications for regulated markets.
• Domestic distribution - sales through pharmaceutical distributors and direct long-term supply contracts with formulators and manufacturers in China.
• Licensing and technology transfer - selective licensing of synthesis routes or intermediates to partners.

• Quality certifications: SFDA/GMP (from 2000) and EU GMP (from 2015) underpin export capability and higher-margin regulated sales.
• R&D focus: development of scalable, cost-efficient synthetic routes for APIs and intermediates; pipeline prioritizes high-volume therapeutic areas (cardio-metabolic, respiratory).
• Manufacturing footprint: multi-site chemical synthesis and downstream purification facilities designed for compliance with international regulatory inspections.

• Listed entity: trades on Shenzhen Stock Exchange, ticker 300702.SZ (IPO/listing in 2017) providing public equity capital for expansion.
• Capital allocation: historically directed toward capacity expansion, EU GMP compliance, and R&D for new APIs and process optimization.
• Investor-facing resources: disclosures, annual reports and filings available through the Shenzhen exchange and company releases.

• Revenue drivers:
  • Volume growth in core API sales (contracts & long-term supply)
  • Price and margin improvement via process optimization and high-purity product lines
  • Geographic diversification - increased export to regulated markets post-EU GMP
• Cost drivers:
  • Raw material and intermediate feedstock prices
  • Regulatory compliance and capital expenditure for sterile/clean facilities
  • R&D and talent retention for synthetic chemistry expertise

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ): History

• Core activities: R&D of innovative and generic small-molecule drugs; production of active pharmaceutical ingredients (APIs); finished-dose manufacturing and domestic sales.
• Growth drivers: capacity expansion, regulatory approvals for new products, and strengthened distribution networks in China and select export markets.
• Corporate governance: high insider ownership aligning leadership with shareholders; steady institutional investor participation.

• How it makes money: sales of APIs and finished formulations to hospitals, clinics, and distributors; contract manufacturing; and licensing of developed compounds.
• Financial posture: market cap of 8.84 billion CNY and EV of 10.30 billion CNY reflect leverage of operating cash flow and asset base to support R&D and production scale-up.
• Ownership implications: 55.40% insider stake provides control stability; 12.89% institutional holding supplies external validation and liquidity.

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ): Ownership Structure

• Mission and Values: Committed to innovation, quality, and social responsibility-aiming to provide high-quality products and services to improve global health.
• Strategic focus: Adheres to the concept of excellence, delicacy, and strength; seeks to build a community of interests with customers, employees, and partners.
• Regulatory & quality credentials: Passed GMP inspections from authorities in the U.S., Europe, Japan, and Korea, ensuring compliance with international standards.

• Contract manufacturing and supply: Producing APIs, intermediates, and finished dosage forms for national and international pharma firms-over half of output supplied to well-known companies.
• Proprietary products & licensed drugs: Sales from in-house formulations and licensed products protected by patents and regulatory approvals.
• R&D-driven product pipeline: Reinvestment of R&D (300M+ CNY) to develop higher-margin products and expand addressable markets.
• Export and compliance advantage: GMP approvals in major markets enable access to higher-value export contracts and partnerships.

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ): Mission and Values

• Structure: operates through six wholly-owned subsidiaries.
• Workforce: employs over 4,500 staff members across R&D, production, quality and commercial functions.
• Registered capital: 182,223,560 CNY.
• Manufacturing footprint: production facilities occupy over 470,000 square meters enabling large-scale chemical and pharmaceutical production.
• Recognition: designated a model high‑tech enterprise within China's Torch Program.

• Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates for:
  • Cardiovascular therapies
  • Anti‑diabetic agents
  • Anti‑atherosclerosis treatments
  • Anticoagulants
  • Anti‑asthmatic drugs
• Fine chemicals production supporting both in‑house APIs and external clients.
• CDMO services: end‑to‑end offerings from route scouting and process development through scale‑up, GMP manufacturing and regulatory support.
• Quality and compliance: multi‑site GMP production and QC labs to serve domestic and export markets.

• API and intermediate sales to branded and generic drug manufacturers (volume‑driven revenue from large‑scale production).
• Contract development and manufacturing fees from CDMO projects (project‑based, technology premium for complex chemistries).
• Fine chemical product margins from custom synthesis and specialty intermediates.
• Technology licensing and collaborative R&D agreements with partners seeking Tianyu's process and scale capabilities.

• R&D: process chemistry, impurity control, analytical method development to support scale‑up and regulatory dossiers.
• Manufacturing: multi‑line GMP reactors, continuous and batch capabilities, downstream purification and formulation support via partners.
• Commercialization: direct sales to domestic and international pharma, plus long‑term CDMO contracts and custom synthesis engagements.

• Large-scale capacity leveraging >470,000 m² facilities to capture volume contracts and lower unit costs.
• Integrated CDMO services that improve project margin capture versus toll manufacturing.
• Focused therapeutic portfolio (cardiometabolic, anticoagulant, respiratory) with stable demand profiles.

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ): How It Works

• Founded in Zhejiang province, Tianyu grew from an API- and intermediate-focused producer into an integrated pharmaceutical manufacturer and CDMO provider.
• Mission: supply high-quality active pharmaceutical ingredients and contract manufacturing solutions while expanding global market reach and pursuing incremental R&D-driven product upgrades.

• Listed on Shenzhen Stock Exchange (300702.SZ); mix of institutional investors, retail shareholders, and management holdings typical for mid-cap Chinese pharma firms.
• Organizational focus centers on API production facilities, intermediate synthesis lines, and specialized CDMO capabilities for small-molecule drugs.

• API and Pharmaceutical Intermediates Sales: Core revenue driver - bulk sales to domestic generics manufacturers and international pharmaceutical companies and traders.
• CDMO Services: Contract development and manufacturing organization services, including custom synthesis, process development, scale-up and commercial manufacturing for third-party pharma clients.
• Specialty Products and Export: High-margin specialty APIs and regulated export channels to markets with GMP-compliant customers.
• Portfolio & Licensing: Occasional licensing or co-development arrangements that generate milestone or royalty income.

• Manufacturing footprint: multi-site chemical synthesis capacity with batches for both commodity APIs and smaller-scale high-value intermediates.
• Quality & Compliance: GMP-certified lines for regulated markets; quality systems support export growth and CDMO contracts.
• Customer segmentation: domestic generic drugmakers, multinational pharmaceutical firms (through CDMO), distributors and exporters.

• Volume sales of commodity APIs drive topline stability; unit margins tend to be lower but provide steady cash flow.
• CDMO and specialty intermediates deliver higher gross margins due to technical barriers, custom processes and regulatory certifications.
• Cost control in raw materials sourcing, route optimization and scale efficiencies are main levers for margin expansion.

• Growth levers: expanding CDMO capacity, upgrading regulated-market GMP compliance, entering higher-value specialty APIs, and export expansion.
• Risks: raw material price volatility, regulatory changes, competition from low-cost producers, and customer concentration in certain API segments.

Zhejiang Tianyu Pharmaceutical Co., Ltd. (300702.SZ): How It Makes Money

• API production and sales - bulk APIs for generic and branded drugs.
• Custom synthesis and contract manufacturing (CMO) - outsourced route development and large-scale production.
• Intermediates and specialty chemicals - upstream inputs sold to drugmakers and chemical firms.
• R&D-driven product upgrades - higher-margin, controlled-substance precursors and novel intermediates.

• Cost structure - capital- and energy-intensive production with scale benefits; vertical integration reduces raw-material volatility.
• Profitability levers - higher-margin specialty APIs, efficiency gains from automation, and pricing power in niche intermediates.
• Risk profile - regulatory and environmental compliance costs, but a low market beta (0.59) signals historically lower share volatility.